Kornimate/medical-research-clean huggingface dataset:
comparison of different training programs on cognitive function

Conditions: Mild Cognitive Impairment (MCI)

Summary: the goal of the project is to identify the most effective exercise modalities in terms of neuroprotective effects and fp improvement. hypothesis: dancing will increase bdnf, gdnf and clu levels to a greater extent than traditional forms of af, resulting in significantly greater improvements in fp in subjects aged ≥ 60 years. the study will involve 60 women aged ≥ 60 years, randomly and equitably assigned to training groups (i.e., resistance training using body weight, dance) and a control group (i.e., a group of physically inactive women). methodology: participants: 60 women aged ≥ 60 randomly and equally assigned to training groups (dance and resistance training) and a control group (i.e., physically inactive women) scientists will compare the impact of different forms of physical activity on cognitive functions

the training interventions will last 6 months. the intensity of physical activity will be determined as a percentage of maximum heart rate (hrmax), assessed based on a fitness test (chester step test), using data from mobile devices monitoring physical activity. cognitive function (cf) levels, and the concentrations of gdnf, bdnf, and clu, as well as the chester step test, will be evaluated twice: once at baseline and once after the training programs. blood samples for measuring neurotrophin and clu levels will be collected in the morning, after an overnight fast (approximately 12 hours since the last meal). the concentrations of neurotrophins and clu will be measured using the elisa method. cf will be assessed using standardized and validated neuropsychological tests. expected outcomes: greater improvement in cf in the dance group compared to the resistance training and control groups, with higher levels of bdnf, gdnf, and clu in the dance group.

Eligibility criteria:
inclusion criteria: * women exclusion criteria: * previous diagnoses of cardiovascular diseases

Keywords: physical activity neurotrophins neuroprotection cognitive function mci
contribution of a prone team in intensive care during the covid-19 epidemic

Conditions: Sars-CoV2

Summary: sars-cov-2 induced by covid 19, involved the hospitalization of 101,932 patients in france, including 4,007 in intensive care (source: santé publique france). alsace was one of the most affected regions on the metropolitan territory with a large number of patients hospitalized at the university hospital of strasbourg. in view of the seriousness of the epidemic and the rapid arrival of new patients requiring mechanical ventilation, 3 new intensive care units have been created on the nhc site alone, making it possible to accommodate a maximum of 111 patients (compared to 52 during normal periods).


Eligibility criteria:
criteria for inclusion : * major patient (≥18 years old) * patient hospitalized in intensive care at the nhc, diagnosed covid + and requiring a vd session of which at least one is performed by the dedicated team. * patient who has not expressed, after information, his or her opposition to the re-use of his or her data for the purposes of this research exclusion criteria : * subject who expressed opposition to participating in the study * subject under guardianship, curatorship or safeguarding of justice

Keywords: mechanical ventilation icu covid-19 sars-cov-2 ards
exploratory study of plaque regression

Conditions: Heterozygous Familial Hypercholesterolemia

Summary: despite the availability of several classes of very effective drugs available to treat heterozygous familial hypercholesterolemia (hefh), there remains a large unmet medical need for new, effective and well tolerated therapies. there are a number of therapies given on a chronic basis to reduce long term risk, such as statins, fibrates, niacin, omega 3 fatty acids, resins, cholesterol absorption inhibitors and antiplatelet or anticoagulant drugs, but subjects with heterozygous familial hypercholesterolemia remain at high risk for cardiovascular events. there is still a need for acute therapies that can lead to rapid pacification of unstable plaque in order to reduce the risk of these events. this study will assess the effects of cer-001 , a recombinant human apo-a-1 based hdl mimetic, on indices of atherosclerotic plaque progression and regression as assessed by 3tesla mri (3tmri)and intravascular ultrasound (ivus) evaluations in patients with hefh.


Eligibility criteria:
inclusion criteria: * male or female subjects at least 18 years old * subject presents heterozygous fh, known chd and receiving maximally tolerated lipid modifying therapy, at stable doses for at least 3 months * ldl-c of \> 110 mg/dl * angiographic evidence of coronary artery disease with suitable "target" coronary artery for ivus exclusion criteria: * confirmed diagnosis of homozygous fh * significant health problems (other than cardiovascular disease) in the recent past including blood disorders, cancer, or digestive problems * female subjects not meeting the study definition of non child-bearing potential * use of an investigational agent within 30 days of the first cer-001 dose * receiving current lipid apheresis

Keywords: heterozygous familial hypercholesterolemia familial hypercholesterolemia hdl mimetic apoa-1
diastasis recti abdominis and abdominal muscles

Conditions: Interrectal Distance; Diastasis Recti; Dimensions of the Muscles of the Lateral Abdominal Wall

Summary: purpose of the study is the assessment of interrectal distance and dimensions of the muscles of the lateral abdominal wall in pregnant and non-pregnant women

* purpose of the study is the assessment of interrectal distance and dimensions of the muscles of the lateral abdominal wall in pregnant and non-pregnant women * assessment via ultrasound measurement transabdominally * 3 groups of participants: 1.) 20 pregnant women, who have never been pregnant before; 2.) 40 pregnant women with their first pregnancy, followed over the course of pregnancy; 3.) 20 women1-5 days after delivery (10 after spontaneous delivery, 10 after planned cesarean section) * comparison between pregnant and non-pregnant women; evaluation of influence of pregnancy and mode of delivery

Eligibility criteria:
inclusion criteria: * non-pregnant women aged 20-45 y with a bmi \< 30 kg/m2 who never were pregnant * pregnant women aged 20-45 y with a bmi \< 30 kg/m2 before pregnancy exclusion criteria: * abdominal pre-operations * chronical lung diseases * constipation * maternal collagenosis * polyhydramnion (afi \> 25) * uterus fibroids \> 10 cm * inability to perform valsalva
ebv-tscm cytotoxic t cells (ctls) for ebv- driven lymphomas/ diseases

Conditions: EBV Lymphoma; Post-transplant Lymphoproliferative Disease (PTLD)

Summary: in this multi-center open-label, non-randomized phase i/ii intervention study three consecutive doses of donor-derived ebv tscm-ctls will be administered to 10 patients with treatment-refractory ebv lymphoma, diseases or ptlds. ebv tscm-ctls will derive from hematopoietic cell transplant (hct) or third-party donors.

epstein barr virus (ebv)-driven lymphomas and diseases are associated with poor prognosis. ebv proteins are recognized by t cells providing opportunities for ebv-specific t-cell therapy. recent findings show that early differentiated t cells (t memory stem cells, tscm) improve the prognosis in chronic viral diseases and are associated with effective tumor cell killing in melanoma patients. tscm might be superior to highly differentiated t cells because of their longevity, robust proliferative potential, and capacity to reconstitute a wide t-cell receptor (tcr) diversity. this project will test the hypothesis that tscm are efficacious for ebv-specific t-cell therapy. clinical-grade enriched ebv-specific tscm-ctls will be prepared and used to treat patients with primary ebv lymphomas, diseases or post-transplant lymphoproliferative disease (ptld) with limited other treatment options.

Eligibility criteria:
patients' inclusion criteria: * group a: patients with ebv driven lymphomas (e.g., nk/t-cell lymphoma), with ebv complications (e.g. hlh, caebv) or patients with primary immunodeficiency disorders with high risk for ebv complications (e.g. scid) with planned allogeneic hct * group b: ebv-driven ptld that develop after a hct or sot for both groups: * all age groups * negative pregnancy test in female patients of childbearing potential. * signed written informed consent of patient or/and parents patients' exclusion criteria: * patients receiving anti-thymocyte globulin or campath within 28 days of infusion * patients with active, acute gvhd grades iii-iv * previous severe reaction to dimethylsulfoxide (dmso) donors' inclusion criteria: * ebv positive serology (vca and epstein-barr nuclear antigen (ebna) immunoglobulin g (igg) positive) * detectable interferon (ifn)-y-secreting t cells (\>100 sfc/10e6 pbmc) measured by elispot to the ebv consensus peptide pool * suitability for blood or hct donation meeting requirements of local institutional guidelines * an informed consent for ebv tscm ctl manufacturing * age \> 18 years donors' exclusion criteria: * detectable ifn-y-secreting t-cells \<100 spot-forming cell (sfc)/10e6 pbmc measured by elispot to ebv select * unwilling and/or unable to donate, according to the donor center

Keywords: ebv-driven lymphomas ebv disease epstein-barr virus (ebv) memory stem cell therapy epstein-barr virus-specific t memory stem cell therapy (ebv-tscm) cytotoxic t-cell line (ctl) t memory stem cells (tscm) t-cell receptor (tcr) post-transplant lymphoproliferative disease (ptld) wnt-β-catenin inhibition hematopoietic cell transplantation (hct) hematopoietic stem cell transplantation (hsct)
use of zarzio® in post-autologous stem cell transplantation procedure

Conditions: Multiple Myeloma; Non-hodgkin Lymphoma; Hodgkin Lymphoma

Summary: there are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (asct). this study aimed to evaluate g-csf efficiency and safety (based on haemograms, transfusion needs and complications) of two biosimilars (zarzio and ratiograstim®) compared to those of neupogen® for our patients who underwent asct.

since 2008, investigator collected data of all patients who underwent asct to treat lymphoma or myeloma. all the patients signed an institutional informed consent form before the harvest of peripheric stem cells (promise program). patients received neupogen® (amgen-sa) between april 2008 and february 2010, and the next group of patients was treated with ratiograstim® (ratiopharm gmbh) until may 2012. the last group of patients received zarzio® (sandoz gmbh) until november 2014. investigator studied the impact of the zarzio® use on biological parameters of the bone marrow recovery, transfusion needs and infectious complications. these parameters were then compared to those of the previous patients which were treated with the two other drugs. the patients were recruited in the university hospital of brest. they were consecutive patients, treated by asct for their high risk lymphoma and myeloma but without selection.

Eligibility criteria:
inclusion criteria: * patients with dlbcl or multiple myeloma * patients who underwent asct in our hospital * patients treated by zarzio® in post-asct phase to accelerate the bone marrow recovery exclusion criteria: * patients who underwent asct but for other diseases * patients who underwent asct for the required diseases but treated with an other biosimilar of filgrastim * patients who did not sign the informed consent

Keywords: biosimilars filgrastim stem cell transplantation lymphoma multiple myeloma
trial of rituximab, bendamustine (rb) for patients with follicular lymphoma refractory or relapsed after treatment with r-chemotherapy in first line

Conditions: Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Summary: evaluate the effectiveness of rituximab, bendamustine (r) in terms of complete response and response complete not confirmed.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. patients with follicular lymphoma grade 1, 2 or 3a, cd20 +, histologically confirmed lymph node biopsy or tissue. 3. follicular lymphoma patients previously treated with the combination of rituximab and chemotherapy (r-chop, r-cvp, r-fludarabine), having received rituximab maintenance, refractory to a first line (excluding radiotherapy) or relapsed after having achieved any response to previous treatment. 4. ecog ≤ 2. 5. signed written informed consent exclusion criteria: 1. clinical suspicion or documentation of histological transformation. 2. patients with hypersensitivity to rituximab. 3. prior autologous or allogeneic transplant. 4. cns infiltration by lf (primary cns lymphoma or lymphomatous meningitis). 5. past or active hepatitis b (at least one of the following markers hbsag, hbe ag, anti-hbc, hbv dna). 6. hcv infection. hiv infection or other conditions of severe immunosuppression. 7. previous neoplasms except non-melanoma skin cancer of the cervix or adequately treated. 8. congestive heart failure\> nyha grade 1. 9. impaired renal function (creatinine\> 1.5 x upper limit of normal, uln) or creatinine clearance \<50 ml / h, not related to lymphoma. 10. impaired liver function (bilirubin, ast / alt or ggt\> 2 x uln) were not related to lymphoma. 11. women who are nursing or pregnant. 12. patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic and not secondary to lymphoma. 13. severe acute or chronic infection in activity. 14. any other concurrent medical or psychological comorbidity that might interfere with participation in this study.
need for antepartum thromboprophylaxis in pregnant women with one prior episode of venous thromboembolism (vte)

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism

Summary: pregnant women with a prior history of venous thromboembolism (vte) are at increased risk of recurrent vte. current guidelines assessing the role of prophylaxis in pregnant women with prior vte are based primarily on expert opinion and the optimal clinical management strategy remains unclear. this multicentre, prospective cohort study aims to test the following hypotheses: 1. antepartum prophylaxis with fixed-dose low molecular-weight heparin (lmwh) is safe, convenient and associated with an acceptably low risk of recurrent vte in women with a single prior episode of vte that was either unprovoked or associated with a minor transient risk factor. (moderate risk cohort) 2. withholding antepartum prophylaxis is safe (recurrence risk \<1%) in pregnant women with a single prior episode of vte provoked by a major transient risk factor. (low risk cohort) all study patients will receive 6 weeks of postpartum prophylaxis.


Eligibility criteria:
inclusion criteria: * confirmed pregnancy (positive serum or urine) * at least 18 years of age * history of one prior episode of vte consisting of dvt (diagnosed by compression ultrasonography \[cus\] or venography) and/or pe (diagnosed by ventilation-perfusion \[v/q\] lung scintigraphy, computed tomographic pulmonary angiography \[ctpa\], or traditional pulmonary angiography) exclusion criteria: * ongoing need for therapeutic anticoagulation for prevention or treatment of cardioembolic stroke * known high-risk thrombophilia (specifically antithrombin deficiency, protein s deficiency, protein c deficiency, homozygosity for the factor v leiden or prothrombin g20210a mutations, antiphospholipid antibody or compound abnormalities) * vte within 3 months of the current pregnancy * clinical risk factor for initial episode of vte, if present, not resolved (excluding pregnancy) * known contraindication to anticoagulation (including active, uncontrolled bleeding or major bleed within the previous 4 weeks) * for patients with prior unprovoked vte, contraindication to lmwh (including allergy, hit, impaired renal function, osteoporosis) * geographic or social factors precluding follow-up * inability or unwillingness to provide informed consent

Keywords: venous thromboembolism thromboembolism deep vein thrombosis pulmonary embolism thromboprophylaxis thrombosis embolism and thrombosis cardiovascular diseases venous thrombosis vascular diseases anticoagulants hematologic agents cardiovascular agents enoxaparin dalteparin tinzaparin pregnancy complications
measuring volume using a 3d scanner and ipad to grade the swelling of legs

Conditions: Limb Volume; Measuring Edema

Summary: we used a new and easy-to-measure ipad 3d scanner to measure swelling in lower limbs because current technology is not easily available or affordable. we want to see how reliable the measurements are and what might affect how consistent they are.

twenty limbs from ten healthy volunteers were scanned using an ipad-based structure sensor and software. initial scans followed standard manufacturer instructions, but high variance rendered data unsuitable for clinical use. to improve accuracy, a standardized scanning protocol was developed, incorporating anatomical calibration, scanning distance standardization, and scanning time control. a 254-mm calf segment was defined using a 3d marker placed on the medial malleolus to ensure consistent volume measurement. the scanning distance was fixed between 50-59 cm to reduce zoom parallax errors, and scans were conducted after 3 pm to minimize diurnal volume fluctuations. multiple technicians performed repeat scans on the same limb to assess intra-observer and inter-observer scan reliability.

Eligibility criteria:
inclusion criteria: * the people in this study will be symptom free volunteers. exclusion criteria: * pre-existing diseased limbs

Keywords: leg swelling 3-d volumetry phlebolymphedema ceap clinical class 3 limb plethysmography lymphedema
treatment -resistant neovascular age-related macular degeneration

Conditions: Macular Degeneration

Summary: the purpose of this study is to determine if treatment of age related macular degeneration (amd) with a new medication,rituximab is effective. to address this issue, investigators propose a clinical trial in which patients with late stage disease, poor vision and who have failed treatment by conventional means will receive rituximab by direct injection into the affected eye and will be followed for improvement in the structure of their retina. age related macular degeneration (amd) is a leading cause of vision loss in the elderly with routine care involving injections in the eye to improve and to prevent worsening of vision. however, some patients do not respond to the medications that we currently have and as such an alternative medication is needed. one potential medication is rituximab, which has been injected into the eye for primary eye cancer, and has been tolerated well and led to patient improvement. investigators will obtain baseline eye tests then plan on injecting this medication in to the eye of our patients with late stage amd, by first placing numbing drops into the eye, then injecting the medication directly into the eye using sterile techniques. investigators will then follow the patient and repeat eye tests to monitor for improvements.


Eligibility criteria:
inclusion criteria: * over the age of 40 * patients who have a diagnosis of wet age-related macular degeneration * patients who have a central visual acuity ,20/200 * patients who have been deemed "treatment-resistant" at the discreation of the treating physician exclusion criteria: * patients with treatment failure for neovascular amd * patients who have tried multiple anti-vegf medication without anatomical or objective improvement
noraxon myoresearch™ software gait analysis evaluation and orthotic gait correction in reducing diabetic foot ulceration or subsequent amputation in patients with a history of a diabetic foot ulceration

Conditions: Diabetic Foot Ulcer

Summary: determining whether the utilization of noraxon myoresearch software gait analysis evaluation and orthotic gait correction can reduce diabetic foot ulceration or subsequent amputation in patients with a history of a diabetic foot ulceration.

the purpose of this study is to identify emerging abnormal structural pathology of the vulnerable re-ulcerative diabetic foot incorporating physical therapy evaluation as well as the noraxon gait analysis to generate quantitative and qualitative gait data. once peak foot pressures and gait pathology is identified, gait remedy is fabricated including either a foot orthotic and/or an ankle foot prosthesis. evaluation of constructed remedy will then be evaluated focusing on gait analysis data to validate decreased plantar foot peak pressures and gait realignment towards the reduction of the diabetic foot re-ulceration and subsequent foot or limb loss.

Eligibility criteria:
inclusion criteria: * history of healed diabetic foot ulceration * over 18 years of age exclusion criteria: patients who are: * under 18 years of age * non-diabetic * non-ambulatory * non-healed wounds.
a study of xeloda (capecitabine) as first-line chemotherapy in patients with advanced or metastatic gastric cancer.

Conditions: Gastric Cancer

Summary: this single arm study will assess the efficacy and safety of xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for advanced or metastatic disease. eligible patients will receive xeloda 1000mg/m2 po twice daily, d1-d10 every 2 weeks (10 days treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m2/day iv, d1 every 2 weeks. the anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * gastric cancer with unresectable locally advanced and/or metastatic disease; * \>=1 measurable lesion; * ambulatory, with ecog performance status \>=1. exclusion criteria: * previous chemotherapy (except adjuvant or neoadjuvant treatment \>=6 months prior to enrollment); * clinically significant cardiac disease or myocardial infarction within last 12 months; * cns metastases; * history of other malignancy within last 5 years, except for cured basal cell cancer of the skin, or in situ cancer of the cervix.